



Original Article

Cite this article: Yildirim Arslan S, Gurses D, and Yuksel S (2024) Evaluation of cardiac functions in children with familial Mediterranean fever. *Cardiology in the Young* 34: 1754–1763. doi: [10.1017/S1047951124000787](https://doi.org/10.1017/S1047951124000787)


Received: 21 November 2023
Revised: 5 February 2024
Accepted: 14 March 2024
First published online: 8 April 2024

Keywords:

Aortic stiffness; familial Mediterranean fever; heart rate variability; MEFV gene; QT dispersion; tissue Doppler echocardiography

Corresponding author:

D. Gurses; Email: dolunayk@yahoo.com

Sema Yildirim Arslan¹, Dolunay Gurses²  and Selcuk Yuksel³

¹Department of Pediatrics, Pamukkale University Faculty of Medicine, Denizli, Turkey; ²Department of Pediatric Cardiology, Pamukkale University Faculty of Medicine, Denizli, Turkey and ³Department of Pediatric Rheumatology and Nephrology, Pamukkale University Faculty of Medicine, Denizli, Turkey

Abstract

Objectives: Familial Mediterranean fever is an autosomal recessive autoinflammatory inherited disease. We aimed to evaluate cardiac involvement in children with familial Mediterranean fever during the attack-free period. **Material and Methods:** The prospective study included 75 familial Mediterranean fever patients during the attack-free period and 50 healthy children. Cardiac evaluation was performed using electrocardiography, 24-hour ambulatory Holter monitoring, and conventional and tissue Doppler echocardiography. Aortic stiffness indices were calculated. **Results:** There were no differences between the groups in age, height, sex, body mass index, and arterial blood pressure parameters ($p > 0.05$). QT and corrected QT dispersion parameters were similar in both groups ($p > 0.05$). The E wave velocity and the E/A ratio of the mitral and tricuspid valves decreased, and the A wave velocity of the tricuspid and mitral valve increased in familial Mediterranean fever by the Doppler echocardiography ($p < 0.05$). The myocardial contraction velocities (Sd), early relaxation velocity (Ed), and Ed/late relaxation velocity (Ad) of both ventricles were decreased in familial Mediterranean fever group, whereas the Ad of both ventricles and the interventricular septum was increased in familial Mediterranean fever group. Aortic strain and distensibility were decreased, and pressure strain elastic modules (Ep), pressure strain normalised (Ep*) by diastolic pressure, and aortic stiffness β index were increased in familial Mediterranean fever patients ($p < 0.05$). When time domain heart rate variability parameters were evaluated, SDNN-i, RMSSD, and PNN50 significantly decreased in familial Mediterranean fever patients ($p < 0.05$), whereas SDNN and SDANN were similar in both groups ($p > 0.05$). **Conclusion:** Our findings showed that cardiac involvement could exist in familial Mediterranean fever patients, even during nonattack periods.

Familial Mediterranean fever is an inherited autoinflammatory disease that presents as recurring episodes of serositis of the peritoneum, pleura, synovium, and, in rare cases, the pericardium. It is characterised by clinical, laboratory, and histological evidence of localised and systemic inflammation.¹ The disease is caused by a mutation in the Mediterranean fever gene.^{2–4} Colchicine is the main therapy that produces complete remission or a marked reduction in the frequency and duration of attacks in most patients.

Cardiovascular disease is a major cause of morbidity and mortality in most autoimmune diseases. However, cardiovascular involvement is uncommon in familial Mediterranean fever.⁵ Familial Mediterranean fever is characterised as progressing with inflammation in the attack-free period as well as during an acute attack.^{6,7} Chronic inflammation can affect the cardiovascular system by causing endothelial dysfunction. Recurrent inflammatory processes during the attacks and the potential chronic persistent subclinical inflammation among attack intervals in familial Mediterranean fever patients may lead to endothelial dysfunction, which is attributed to arteriosclerosis. Inflammation increases arterial stiffness. As a result of inflammation, cytokines increase in circulation. Increased circulating inflammatory mediators (tumor necrosis factor- α , interleukin-2 receptor, interleukin-1b, interleukin-6, interleukin-8, and interleukin-12) impair collagen and elastin in the aortic intima. Decreased elastin causes increased arterial stiffness.^{8,9} The aortic stiffness reflects aortic elasticity. Aortic elasticity is closely associated with cardiovascular mortality. Although pericarditis is a common cardiac manifestation of familial Mediterranean fever, few studies have reported arrhythmia, atherosclerosis, ventricular dysfunctions, decreased heart rate variability, and abnormalities in aortic elasticity.^{10–13} We aimed to evaluate possible cardiac involvement in children with familial Mediterranean fever during the attack-free period using electrocardiography and conventional and tissue Doppler echocardiography. Additionally, we evaluated the aortic stiffness index and time-domain heart rate variability.

Methods

Patients/participants

A single-centre, prospective study included 75 children (39 girls) with familial Mediterranean fever, and 50 healthy controls (25 girls) recruited from the outpatient clinic at Pamukkale University Faculty of Medicine. The diagnosis of familial Mediterranean fever was based on the Tel Hashomer criteria.⁶ The control group consisted of 50 healthy volunteers who were age- and sex matched with the study group.

Patients with obesity, diabetes mellitus, thyroid dysfunction, hypertension, arrhythmia, infectious disease, electrolyte imbalance, chronic renal failure, hyperlipidaemia, chronic liver disease, malignancy, congenital, or acquired heart disease, cardiomyopathy, and amyloidosis were excluded. Patients who were currently experiencing an attack period or receiving drugs that could influence the cardiac autonomic nervous system, such as antipsychotics, antidepressants, and antihistaminics, were excluded from the study. All familial Mediterranean fever patients were using regular colchicine therapy. Clinical and laboratory assessments of the patients were performed during the attack-free period and at least three weeks after the attack. The healthy controls consisted of outpatients who applied for innocent murmur, presyncope, and chest pain, but did not detect cardiologic pathology.

We recorded the epidemiological data, clinical symptoms, date of diagnosis, age at onset, age at diagnosis, family history, disease duration, clinical phenotype, attack duration and frequency, treatment duration, response to treatment, and genetic analysis of Mediterranean fever gene mutations in familial Mediterranean fever patients. Patients with familial Mediterranean fever were evaluated by dividing them into two groups according to the presence (or absence) of the M694V mutation.

Anthropometric parameters were evaluated in all patients. Body mass index was calculated as defined previously.¹⁴ Hemogram and biochemical parameters including serum electrolytes, C-reactive protein, fibrinogen, erythrocyte sedimentation rate, triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein values were evaluated in the study and control groups. All subjects rested in the supine position for 15 minutes, and then their right brachial artery pressure was measured by a sphygmomanometer with the appropriate cuff. Both systolic (Ps) and diastolic blood pressure (Pd) were measured. All the patients and control subjects performed electrocardiography, conventional, and tissue Doppler echocardiography. Twenty-four-hour Holter recordings were obtained for all subjects. All data were evaluated by the same paediatric cardiologist.

This study was approved by the local ethics committee and fulfilled the ethical guidelines of the most recent Helsinki Declaration. All parents of the children gave written informed consent.

Electrocardiography

Standard resting 12-lead electrocardiogram was recorded at 25 mm/s paper speed. Heart rate was calculated from the R-R interval of the tracings. QT intervals were measured manually in a blinded fashion from the onset of the QRS complex to the end of the T wave on the iso-electric line by the same physician. For each lead, three consecutive QT intervals were measured and averaged. The QT dispersion was defined as the difference between the maximum and minimum QT intervals in one ECG record. The QT interval

was corrected using the heart rate according to the Bazett's formula ($QTc = QT \sqrt{RR}$),¹⁵ and the QTc dispersion was calculated.

Echocardiography

All patients and members of the control group underwent 2D, M-mode, Doppler, and the tissue Doppler echocardiography ultrasounds using a Vivid 7 model echocardiography and multi-frequency transducer (2.5–4 MHz; GE Vingmed Company, Horten, Norway). All subjects were rested and lying in the lateral decubitus position during the examinations. The means of three consecutive measurements were recorded. M-mode measurements were made at the level of the tips of the mitral valve leaflets in the parasternal long-axis view of the left ventricle.¹⁶ The standard parameters measured in the parasternal long axis by M-mode echocardiography were LV posterior wall end-diastolic thickness, left ventricular end-diastolic dimension, and interventricular septum end-diastolic thickness. LV ejection fractions and shortening fractions were calculated as defined previously.¹⁷ Left ventricular mass and left ventricular mass index were calculated using the following standard formulas:^{18,19} $LVM = [0.8 \times 1.04 ((LVEDD + IVSTd + LVPWtd)^3 - (LVEDD^3)) + 0.6]$ and $LVMi = LVM$ divided by height to the 2.7 power. Relative wall thickness was calculated using the formula:¹⁹ $RWT = (IVSTd + LVPWtd)/LVEDD$. Conventional Doppler blood velocities were measured for mitral and tricuspid valves using an apical four-chamber view (peak E and A waves), and the E/A ratio was determined.

Tissue Doppler echocardiography

Tissue Doppler echocardiography mode of the same machine was used by lowering the velocity range (0–30 cm/s) to determine myocardial velocities and setting the Doppler gain to achieve maximum colour information on the myocardium. Pulsed-wave tissue Doppler echocardiography was used to record myocardial contraction velocities (S), early and late relaxation velocities (Ed and Ad, respectively) in basal portions of the LV (at the level of the lateral mitral annulus), right ventricle (RV) (at the level of the lateral tricuspid annulus), and interventricular septum in the apical four-chamber view. The ratio of peak velocities in early and late relaxation (Ed/Ad) was determined for the assessment of diastolic function.

Elastic properties of the aorta

A long-axis view of the abdominal aorta of the subxiphoid area was recorded, and the maximum systolic (Ds) and minimum diastolic diameter (Dd) were measured by M-mode echocardiography. Aortic strain (S) was calculated using the changes in aortic diameters, and pressure strain elastic modules were calculated from the aortic strain and the changes in artery systolic and diastolic pressure using the formulas $S = (Ds - Dd)/Dd$ and $Ep = (Ps - Pd)/S$. Pressure strain normalised (Ep^*) by diastolic pressure was calculated using the following equation: $Ep^* = Ep/Pd$. Aortic distensibility (DIS) and aortic stiffness β index (β SI) were calculated according to the previously proposed and evaluated equations as $DIS = [2(Ds - Dd)/Dd(Ps - Pd)] \times 10^{-6} \text{ cm}^2 \text{ dyne}^{-1}$ and $SI = \ln(Ps/Pd)/[(Ds - Dd)/Dd]$.^{20–22} S and DIS represent the distensibility or elasticity of the aortic wall; Ep, Ep^* , and β SI represent the stiffness of the aortic wall. Ep and Ep^* are the mean stiffness of the aorta.

Table 1. Demographic and clinical characteristics in the study and control groups

	FMF (n = 75)	Control (n = 50)	p-value
Age (years), mean± SD	9.8 ± 3.8	9.3 ± 3.8	>0.05
Sex (boy/girl), (n)	36/39	25/25	>0.05
Weight (kg), mean± SD	34.6 ± 16.1	34.5 ± 16.7	>0.05
Height (cm), mean± SD	136.0 ± 22.2	133.4 ± 24.2	>0.05
BSA (m ²), mean± SD	1.12 ± 0.34	1.11 ± 0.35	>0.05
BMI (kg/m ²), mean± SD	17.6 ± 3.3	18.2 ± 3.7	>0.05
Systolic BP (mmHg), mean± SD	97.8 ± 13.4	101.2 ± 11.7	>0.05
Diastolic BP (mmHg), mean± SD	60.7 ± 8.7	63.1 ± 8.5	>0.05
Heart rate (beat/minute), mean± SD	79.1 ± 13.6	78.2 ± 15.4	>0.05
In the FMF group;			
Clinic manifestation			
Fever, n (%)	74 (98.7)	–	–
Abdominal involvement, n (%)	67 (89.3)	–	–
Chest involvement, n (%)	17 (22.7)	–	–
Arthritic involvement, n (%)	48 (64)	–	–
Duration of disease (years), mean± SD	2.9 ± 2.5	–	–
Age at diagnosis (years), mean± SD	7 ± 3.6	–	–
Time elapsed from the onset of symptoms to diagnosis, years, mean± SD	1.44 ± 1.35	–	–

SD = Standard deviation; BSA = Body surface area; BMI = Body mass index; BP = blood pressure; FMF = Familial Mediterranean fever.

Twenty-four-hour ambulatory Holter monitoring

Patients and controls underwent 24-hour ambulatory Holter monitoring. Continuous ambulatory ECG monitoring was recorded using the Cardioline Walk400h Holter software *Cardioline*® version 1.2 for Windows. The recordings consisted of three lead configurations of electrocardiographic data. Twenty-four-hour mean RR (mean of all filtered RR intervals over the length of the analysis) and nighttime mean RR (mean of all filtered RR intervals for 5 consecutive hours during quiet sleep) were calculated. Heart rate variability was analysed using time domain indices from the Holter tapes. The following five measures²³ were examined:

SDDNN: Standard deviation of all filtered RR intervals in the entire 24-hour ECG recording,

SDNN-i: Mean of the standard deviations of all filtered RR intervals for all 5-min segments of the analysis,

SDANN-i: Standard deviation of the means of all filtered RR intervals for all 5-min segments of the analysis,

RMSSD: Square root of the mean of the sum of squares of differences between adjacent filtered RR intervals over the length of the analysis,

PNN50: Percentage of differences between adjacent filtered RR intervals greater than 50 ms for the whole analysis.

Statistical analysis

All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS 21, Inc., Chicago, IL, USA). The distribution of continuous variables was performed using the Shapiro–Wilk test. Statistical analyses included chi-square for categorised data, student t-test for parametric data, and

Mann–Whitney U and Kruskal–Wallis for nonparametric data. Statistical significance was considered at p-values less than 0.05. All data were expressed as the mean and standard deviation or medians (interquartile range) for continuous variables, and categorical variables were expressed as percentages, depending on the normality distribution.

Results

The study group consisted of 75 children with familial Mediterranean fever and 50 healthy controls. The mean age was 9.8 ± 3.8 years, and 36 (48%) participants were boy in the familial Mediterranean fever group. The control group had a mean age of 9.3 ± 3.8 years, and there were 25 (50%) boys. There was no significant difference between the familial Mediterranean fever and control groups in sex, age, blood pressure, or BMI ($p > 0.05$). The demographic characteristics of the baseline study population are shown in Table 1.

The mean age at diagnosis of the children with familial Mediterranean fever was 7 ± 3.6 years. The time elapsed from the onset of symptoms to diagnosis was 1.44 ± 1.35 years. The mean duration of the disease was 2.9 ± 2.5 years (0.5–12.5) (Table 1). Of the patients, 40 (53.3%) had family histories of familial Mediterranean fever.

An Mediterranean fever gene mutation was detected in at least one allele in 70 (98.5%) of the 71 patients with known mutations. Thirty-one (44.4%) variants were reported as homozygous, 25 (35.7%) as compound heterozygous, and only 14 (20%) as heterozygous. M694V was the most common homozygous variant (n: 38, 53.5%).

The hemogram results, biochemical parameters, and lipid profiles were the same in the study and control groups, except for

Table 2. Laboratory characteristics in the study and control groups

	FMF (n = 75) (mean ± SD)	Control (n = 50) (mean ± SD)	p-value
Hemoglobin (g/dL)	12.9 ± 1.0	13.1 ± 1.2	>0.05
White blood cell (K/uL)	7.6 ± 2.3	8.3 ± 3.1	>0.05
Platelet count (K/L)	297.6 ± 73.1	297.6 ± 66.7	>0.05
Urea (mg/dL)	22.4 ± 6.3	22.6 ± 4.4	>0.05
Creatinine (mg/dL)	0.5 ± 0.1	0.5 ± 0.1	>0.05
Sodium (mmol/L)	139.6 ± 2.1	138.9 ± 2.3	>0.05
Potassium (mmol/L)	4.4 ± 0.4	4.4 ± 0.4	>0.05
Chloride (mmol/L)	103.3 ± 2.6	102.6 ± 2.3	>0.05
Magnesium (mg/dL)	2.0 ± 0.1	2.0 ± 0.1	>0.05
Calcium (mg/dL)	9.7 ± 0.4	9.7 ± 0.4	>0.05
Phosphorus (mg/dL)	4.6 ± 0.6	4.5 ± 0.5	>0.05
CRP (mg/dL)	0.43 ± 0.98	0.18 ± 0.45	>0.05
ESR (mm/hour)	16.1 ± 11.7	10.4 ± 6.6	0.03
Fibrinogen (mg/dL)	264.2 ± 51.4	248.7 ± 43.9	>0.05
Total cholesterol (mg/dL)	145.2 ± 28.4	148.5 ± 21.7	>0.05
Triglyceride (mg/dL)	87.7 ± 40.9	85.7 ± 38.3	>0.05
LDL- cholesterol (mg/dL)	75.4 ± 24.3	76.8 ± 17.9	>0.05
HDL- cholesterol (mg/dL)	51.2 ± 15.4	53.4 ± 12.7	>0.05
VLDL- cholesterol (mg/dL)	18.3 ± 10.1	18.6 ± 11.8	>0.05

CRP = C reactive protein; ESR = erythrocyte sedimentation rate; FMF = Familial Mediterranean fever; HDL = high-density lipoprotein; LDL = low-density lipoprotein; VLDL = very-low-density lipoprotein; SD = Standard deviation.

the erythrocyte sedimentation rate levels ($p > 0.05$) (Table 2). Although the erythrocyte sedimentation rate was within normal values, the mean erythrocyte sedimentation rate levels were higher in the familial Mediterranean fever group than in the control group ($p = 0.03$, Table 2).

Turning to the evaluation of ECG parameters, the mean QTd and cQTd were longer in the children with familial Mediterranean fever than in the control group, although there were no significant differences between the groups ($p > 0.05$). Table 3 shows the QT and cQT parameters of the groups.

When the echocardiographic parameters of the familial Mediterranean fever and control groups were compared, we detected that LVPWTd, LVd, IVSTd, LVs, LV-EF, LV-FS, LVM, LVMI, and RWT were similar in the groups. No significant difference in these parameters was found between the groups ($p > 0.05$, Table 4).

In the comparison of conventional Doppler echocardiographic parameters between the familial Mediterranean fever and control groups, the peak mitral E wave velocity and mitral and tricuspid E/A ratios were lower in the familial Mediterranean fever group, whereas the peak mitral and tricuspid A wave velocities were higher in the familial Mediterranean fever group than in the healthy controls ($p < 0.05$) (Table 5).

When the tissue Doppler echocardiographic parameters were evaluated, the Sd, Ed, and Ed/Ad of both ventricles were lower in the familial Mediterranean fever group than in the controls, whereas the Ad of both the ventricles and interventricular septum

Table 3. QT and QTc parameters in the study and control groups

QT interval and dispersion	FMF (n = 75) (mean ± SD)	Control (n = 50) (mean ± SD)	p-value
Mean QT interval (ms)	327.6 ± 31.0	319.1 ± 30.9	>0.05
Mean cQT interval (ms)	388.4 ± 17.6	388.3 ± 19.4	>0.05
Mean QTd (ms)	61.1 ± 20.1	60.9 ± 18.5	>0.05
Mean cQTd (ms)	93.5 ± 24.6	88.5 ± 26.1	>0.05
QT _{min} (ms)	290.9 ± 30.9	281.1 ± 29.9	>0.05
QT _{max} (ms)	352.1 ± 35.2	342.0 ± 30.3	>0.05
cQT _{min} (ms)	334.9 ± 22.3	339.2 ± 18.4	>0.05
cQT _{max} (ms)	428.5 ± 20.0	427.8 ± 19.3	>0.05

cQT = Corrected QT; QTd = QT interval dispersion; cQTd = corrected QT dispersion; min = minimum; max = maximum; SD = Standard deviation; FMF = Familial Mediterranean fever.

Table 4. Echocardiographic parameters in the study and control groups

	FMF (n = 75) (mean ± SD)	Control (n = 50) (mean ± SD)	p-value
LVPWTd (mm)	7.9 ± 1.2	7.7 ± 1.2	>0.05
LVd (mm)	36.4 ± 5.7	37.2 ± 5.4	>0.05
IVSTd (mm)	7.8 ± 1.1	7.9 ± 1.1	>0.05
LVs (mm)	20.4 ± 3.6	20.7 ± 3.1	>0.05
LV-EF (%)	82.1 ± 3.7	82.1 ± 4.7	>0.05
LV-FS (%)	44.0 ± 4.2	44.0 ± 4.7	>0.05
LVM (gr)	92.3 ± 41.5	91.9 ± 43.3	>0.05
LVMI ($\text{g}/\text{m}^2.7$)	39.2 ± 5.1	38.7 ± 9.9	>0.05
RWT	0.43 ± 0.06	0.42 ± 0.05	>0.05
RVd (mm)	24.0 ± 3.6	22.9 ± 4.3	>0.05
RVs (mm)	14.6 ± 2.4	13.8 ± 2.4	>0.05
RVEF	75.9 ± 8.6	76.4 ± 8	>0.05
RVFS	38.6 ± 7.1	39.1 ± 7.4	>0.05
AA (mm)	14.8 ± 2.2	14.9 ± 2.4	>0.05
LA (mm)	25.9 ± 4.3	25.2 ± 3.7	>0.05

LVPWTd = Left ventricular posterior wall end-diastolic thickness; LVd = left ventricular end-diastolic dimension; IVSTd = interventricular septum thickness diastolic; LVs = left ventricular end-systolic dimension; LA = left atrium; AA = aortic annulus; LVM = left ventricle mass; LVMI = left ventricle mass index; RWT = relative wall thickness; EF = ejection fraction; FS = fractional shortening; FMF = Familial Mediterranean fever; SD = Standard deviation.

was higher in the familial Mediterranean fever group than in the control group ($p < 0.05$). The tissue Doppler echocardiographic parameters are presented in Table 6.

While the aortic systolic and diastolic diameters were similar in the two groups ($p > 0.05$), the aortic strain and distensibility were lower in the study group than in the controls, and the E_p , E_p^* , and aortic stiffness β index were higher in the study group ($p < 0.05$, Table 7).

The time-domain heart rate variability parameters were compared between the groups through 24-hour ambulatory Holter monitoring. There were no statistically significant

Table 5. Conventional Doppler echocardiographic parameters in the study and control groups

	FMF (n = 75) (mean ± SD)	Control (n = 50) (mean ± SD)	p-value
Mitral E velocity (cm/s)	93.8 ± 13.3	98.6 ± 10.0	0.032
Mitral A velocity (cm/s)	52.7 ± 9.1	46.2 ± 6.5	<0.001
Mitral E/A ratio	1.8 ± 0.3	2.2 ± 0.3	<0.001
Tricuspid E velocity (cm/s)	65.4 ± 8.3	67.7 ± 7.6	>0.05
Tricuspid A velocity (cm/s)	42.1 ± 8.1	35.2 ± 6.3	<0.001
Tricuspid E/A ratio	1.6 ± 0.3	2.0 ± 0.3	<0.001

E = peak early diastolic velocity; A = peak late diastolic velocity; IVRT = isovolumetric relaxation time; DT = deceleration time; MPI = myocardial performance index; RT = relaxation time; E': peak early diastolic tissue Doppler velocity; S' = peak systolic tissue Doppler velocity; A' = peak late diastolic tissue Doppler velocity; cm/s = centimeter per second; ms = millisecond; FMF = Familial Mediterranean fever; SD = Standard deviation.

Table 6. The tissue Doppler echocardiographic parameters in the study and control groups

	FMF (n = 75) (mean ± SD)	Control (n = 50) (mean ± SD)	p-value
Sdm (cm/s)	9.2 ± 1.5	10.0 ± 2.6	0.019
Edm (cm/s)	15.7 ± 3.2	16.9 ± 2.3	0.032
Adm (cm/s)	8.2 ± 2.5	6.1 ± 1.3	<0.001
Edm/Adm	2.0 ± 0.5	2.8 ± 0.6	<0.001
Em/Edm	6.2 ± 1.7	5.9 ± 1.0	>0.05
Sdivs (cm/s)	8.2 ± 1.5	8.4 ± 1.5	>0.05
Edivs (cm/s)	13.6 ± 2.0	14.5 ± 1.7	0.013
Adivs (cm/s)	7.6 ± 1.7	5.5 ± 1.1	<0.001
Edivs/Adivs	1.9 ± 0.5	2.7 ± 0.6	<0.001
Sdt (cm/s)	13.0 ± 1.7	13.7 ± 2.1	0.03
Edt (cm/s)	15.7 ± 2.7	17.3 ± 2.1	<0.001
Adt (cm/s)	12.9 ± 3.1	8.2 ± 1.7	<0.001
Edt/Adt	1.3 ± 0.3	2.2 ± 0.5	<0.001

Adivs = peak atrial contraction velocity for the interventricular septum; Adm = peak atrial contraction velocity for the left ventricle; Adt = peak atrial contraction velocity for the right ventricle; Edivs = peak early relaxation velocity for the interventricular septum; Edm = peak early relaxation velocity for the left ventricle; Edt = peak early relaxation velocity for the right ventricle; Eivs = peak early mitral inflow velocity; Sdivs = peak systolic velocity for the interventricular septum; Sdm = peak systolic velocity for the left ventricle; Sdt = peak systolic velocity for the right ventricle; RTdt = relaxation time for the right ventricle; RTdivs = relaxation time for the interventricular septum; RTdm = relaxation time for the left ventricle. DTdt = Deceleration time for the right ventricle; DTdivs = Deceleration time for the interventricular septum; DTdm = Deceleration time for the left ventricle; MPIdt = myocardial performance index for the right ventricle. MPIdivs = myocardial performance index for the interventricular septum; MPIdm = myocardial performance index for the left ventricle.

differences in the maximal, minimal, or average RR intervals. SDNN-i, RMSSD, and pNN50 were significantly lower in the children with familial Mediterranean fever compared with the

Table 7. The aortic elasticity parameters in the study and control groups

	FMF (n = 75) (mean ± SD)	Control (n = 50) (mean ± SD)	p-value
Dd (mm)	10.3 ± 1.9	10.6 ± 1.7	>0.05
Ds (mm)	7.7 ± 1.4	7.5 ± 1.2	>0.05
Aortic strain, (%)	0.35 ± 0.11	0.42 ± 0.13	0.002
Ep (NxM ⁻²)	116.5 ± 44.2	100.4 ± 43.4	0.047
Ep*	1.95 ± 0.78	1.61 ± 0.74	0.017
Distensibility (10 ⁻⁶ cm ² dyne ⁻¹)	2 ± 0.9	2.3 ± 0.9	0.039
β SI	1.1 ± 0.4	0.9 ± 0.2	0.024

SD = standard deviation; FMF = familial Mediterranean fever; Dd - aortic diameter in diastole; Ds - aortic diameter in systole; Ep = pressure strain elastic modulus; Ep* = pressure strain normalized by diastolic pressure; β SI - aortic stiffness β index.

controls (p < 0.05). The other time-domain parameters, including SDNN and SDANN, were similar in the two groups (p > 0.05, Table 8).

When familial Mediterranean fever patients with and without the M694V mutation were evaluated, the mean C-reactive rate and erythrocyte sedimentation rate were higher in patients with the M694V mutation than in patients without it (p < 0.05). Mean QT, QTd, and cQTd levels were higher in patients with the M694V mutation, but there were no significant differences (p > 0.05). There were also no significant differences in conventional or tissue Doppler echocardiographic parameters or 24-hour ambulatory Holter monitoring parameters between the familial Mediterranean fever children with and without M694V mutations. Aortic strain and distensibility were lower and Ep, Ep*, and aortic stiffness β index were higher in patients with M694V, although there were no statistically significant differences (p > 0.05, Table 9).

Discussion

We showed that QT and corrected QT dispersion parameters were similar and the E wave velocity and the E/A ratio of the mitral and tricuspid valves, the Sd, the Ed, and Ed/Ad of both ventricles decreased, and the A wave velocity of the tricuspid valve, the Ad of both ventricles and the interventricular septum increased in familial Mediterranean fever patients. Aortic strain and distensibility were decreased, and Ep, Ep* by diastolic pressure, and the aortic stiffness β index were increased in the familial Mediterranean fever patients. SDNN-i, RMSSD, PNN50 significantly decreased in the familial Mediterranean fever patients, whereas SDNN and SDANN were similar in both groups in our study.

Familial Mediterranean fever is an autosomal recessive disease that is the most frequent autoinflammatory disorder and that is characterised by short, repeated, and self-limiting attacks of fever and serositis.²⁴ Although familial Mediterranean fever has been observed in all age groups, it has been reported that symptoms usually begin at the age of 3–15 years.¹³ In recent years, studies have reported that increasingly younger children are being diagnosed with the disease.^{25,26} The mean age of diagnosis in children with familial Mediterranean fever was reported as 7.5 years by Yalcinkaya et al.²⁵ and 7.6 years by Ece et al.²⁶ In our study, the mean age at diagnosis was seven years, which is consistent with previous studies. We think that the reason for the

Table 8. Time-domain HRV parameters in the study and control groups.

	FMF (n = 75) (mean ± SD)	Control (n = 50) (mean ± SD)	p-value
Mean RR time (ms)	699.8 ± 72.7	726.1 ± 94.7	>0.05
Mean heart rate/min	86.9 ± 8.8	83.9 ± 9.2	>0.05
SDNN (ms)	141.3 ± 32.9	147.9 ± 31.2	>0.05
SDANN (ms)	121.8 ± 29.6	125.4 ± 29.6	>0.05
SDNN index (ms)	85.5 ± 21.2	104.9 ± 31.9	<0.05
RMSSD (ms)	62.8 ± 28.3	77.6 ± 36.6	<0.05
pNN50 (%)	24.8 ± 12.3	32 ± 13.7	<0.05

decrease in the age of diagnosis of familial Mediterranean fever is that society and health professionals are becoming better informed about familial Mediterranean fever, and therefore the disease is being diagnosed at a younger age.

Acute phase reactants, including C-reactive protein, erythrocyte sedimentation rate, and fibrinogen, are known to be elevated during the acute phase of familial Mediterranean fever.²⁷ The mean erythrocyte sedimentation rate was significantly higher in children with familial Mediterranean fever who were in the attack-free period compared to the control group in our study. The mean C-reactive protein, fibrinogen, and haemogram levels were similar in the two groups. The higher erythrocyte sedimentation rate detected in the attack-free period in our study also reinforces that inflammation continues even in the asymptomatic period in familial Mediterranean fever patients. Therefore, these patients are at risk for cardiovascular disease.^{5,27} We evaluated possible cardiac involvement in children with familial Mediterranean fever globally using electrocardiography, conventional and tissue Doppler echocardiography, and 24-hour ambulatory Holter monitoring during the attack-free period.

Prolonged QT dispersion indicates ventricular inhomogeneity. Although many studies have measured QT parameters in adult familial Mediterranean fever patients, only three have evaluated QT parameters in children with familial Mediterranean fever.^{11,12,28–34} Studies of adults with familial Mediterranean fever have shown that QT parameters are similar in familial Mediterranean fever and control groups.^{32–34} However, two studies reported statistically higher values of ventricular polarisation parameters in adult familial Mediterranean fever patients.^{12,30} In the studies that evaluated paediatric familial Mediterranean fever patients, long QTc was found in only one study, conducted by Farag et al.²⁸ In contrast, Koca²⁹ and Sahin et al.³¹ showed that the QT dispersion parameters of the familial Mediterranean fever children and controls were similar. We also found longer QT dispersion parameters in children with familial Mediterranean fever, although the difference was not statistically significant. We speculate that the QT parameters of the groups in our study were similar because of the young mean age of the children, the short duration of the disease, and the minimal delay in diagnosis. Previous studies did not evaluate the relationship between the presence of the M694V mutation and QT parameters, while we evaluated QT parameters with and without the M694V mutation, finding that QT parameters were longer in the children with the M694V mutation but not significantly so.

Many studies have demonstrated the presence of diastolic dysfunction in patients with familial Mediterranean fever.^{10–13,35,36} The main pathophysiologic mechanisms for diastolic dysfunction are increased cytokines in circulation, decreased nitric oxide, and atherosclerosis.³⁷ Thus, the underlying mechanism of ventricular diastolic dysfunction is a subclinical, chronic, continuous inflammatory process.^{10–13,34,38} Tissue Doppler echocardiography is able to evaluate diastolic functions because it is not affected by preload or afterload. Many studies have used conventional echocardiography with familial Mediterranean fever patients,^{12,13,32,39–43} while tissue Doppler echocardiography has only been used in three paediatric studies.^{10,40,44} Two of these studies evaluated only the left ventricle, while the other evaluated both. Baysal et al.¹⁰ evaluated only left ventricular function, finding the presence of diastolic dysfunction in children with familial Mediterranean fever. The other study of the left ventricle showed that the values for different tissue Doppler echocardiography parameters (the S and A waves of the septal mitral annulus) were lower in children with familial Mediterranean fever.⁴⁴ The third study reported that left ventricular function was preserved while right ventricular diastolic function was impaired in children with familial Mediterranean fever, which is an early sign of cardiac involvement.⁴⁰ They speculated that right ventricular diastolic dysfunction may be more important due to the nonconcentric contraction of the right ventricle and its complex structure.⁴⁰ In our study, we evaluated both ventricular functions to be similar to those found by Ozdemir et al.⁴⁰ Thus, we found that the Sd, Ed, and Ed/Ad waves of both ventricles were decreased, and the Ad waves of both ventricles and the interventricular septum were increased in the familial Mediterranean fever group. We also demonstrated that both right and left ventricular function indices are impaired in children with familial Mediterranean fever.

It is known that increased aortic stiffness is an independent risk factor for cardiovascular diseases.^{45–47} Because aortic stiffness parameters are impaired in autoimmune diseases, it is thought that these parameters may also increase in familial Mediterranean fever. While studies in adults with familial Mediterranean fever have shown an increase in aortic stiffness, one study has shown that there is no difference between the control group and adults with familial Mediterranean fever.^{13,42,48} Only two have evaluated the aortic stiffness in children with familial Mediterranean fever. Sgouropoulou et al.⁴⁹ found that carotid-femoral pulse wave velocities of the familial Mediterranean fever children and controls were similar. Turkuçar et al.⁵⁰ showed that the stiffness of descending aorta was lower. We found that aortic strain and distensibility were decreased, and aortic stiffness β index, Ep, and Ep* were increased in children with familial Mediterranean fever. We think that increased aortic stiffness indices reflect the presence of subclinical effects in patients with familial Mediterranean fever.

Heart rate variability is a simple and reliable tool commonly used to assess the autonomic nervous system. Few studies showed cardiovascular effects and autonomic dysfunction in patients with familial Mediterranean fever using heart rate variability.^{12,51–53} On the other hand, only two studies have evaluated heart rate variability in children with familial Mediterranean fever.^{31,54} Fidancı et al.⁵⁴ showed that SDNN values were lower; RMSSD and PNN50 values were normal in the uncomplicated children with familial Mediterranean fever during the attack-free period. Otherwise, Sahin et al.³¹ detected that time-domain heart rate variability parameters of the familial Mediterranean fever children and healthy subjects were similar. We also demonstrated a significant decrease in the time domain of heart rate variability

Table 9. Laboratory, electrocardiographic, conventional echocardiographic, tissue doppler echocardiographic, elastic properties of the aorta, and heart rate variability measurements in FMF patients with and without M694V mutation.

	M694V mutation (+) n = 38 (mean ± SD)	M694V mutation (-) n = 33 (mean ± SD)	p-value
Laboratory parameters			
CRP (mg/dL)	0.7 ± 1.2	0.1 ± 0.3	<0.05
ESR (mm/hour)	19.8 ± 13.6	12.1 ± 7.6	<0.05
QT parameters			
Mean QT interval (msn)	328.5 ± 32.7	325.9 ± 30	>0.05
Mean QTc interval(msn)	387.5 ± 17.7	390 ± 18	>0.05
Mean QTd (msn)	61.4 ± 18.1	61 ± 23.1	>0.05
Mean QTcd (msn)	94.6 ± 26.2	93.9 ± 23.2	>0.05
Echocardiographic parameters			
LVPWTd (mm)	7.7 ± 1.2	8.1 ± 1.1	p > 0.05
LVd (mm)	35.7 ± 6.2	37.5 ± 5.1	p > 0.05
IVSTd (mm)	7.6 ± 1.2	8 ± 1.1	p > 0.05
LVs (mm)	19.8 ± 3.7	21.1 ± 3.7	p > 0.05
LV-EF (%)	81.9 ± 3.1	82.6 ± 4.3	p > 0.05
LV-FS (%)	43.6 ± 3.3	44.6 ± 5	p > 0.05
LVM (gr)	85.3 ± 43	102.6 ± 40	p > 0.05
LVMI (g/m ^{2.7})	39.7 ± 5.7	38.8 ± 4.6	p > 0.05
RWT	0.42 ± 0.06	0.43 ± 0.05	p > 0.05
RVd (mm)	23.8 ± 3.3	24.5 ± 3.8	p > 0.05
RVs (mm)	14.5 ± 2.5	14.8 ± 2.5	p > 0.05
RVEF	76.4 ± 6.7	76.4 ± 8.6	p > 0.05
RVFS	38.7 ± 6	39 ± 7.3	p > 0.05
AA	14.5 ± 2.3	15.2 ± 2.2	p > 0.05
LA	25.7 ± 4.5	26.3 ± 4.3	p > 0.05
Conventional Doppler echocardiographic parameters			
Mitral E velocity (cm/s)	94.5 ± 10.4	93.1 ± 12.7	>0.05
Mitral A velocity (cm/s)	53 ± 9.3	52.2 ± 8.6	>0.05
Mitral E/A ratio	1.8 ± 0.3	1.8 ± 0.2	>0.05
Tricuspid E velocity (cm/s)	64.6 ± 8.2	66.2 ± 8.1	>0.05
Tricuspid A velocity (cm/s)	41.7 ± 8	42.6 ± 7.7	>0.05
Tricuspid E/A ratio	1.5 ± 0.3	1.6 ± 0.2	>0.05
The tissue Doppler echocardiographic parameters			
Sdm (cm/s)	8.9 ± 1.5	9.1 ± 1.3	>0.05
Edm (cm/s)	15.5 ± 3.1	16 ± 3.3	>0.05
Adm (cm/s)	8.1 ± 2.9	8.1 ± 1.5	>0.05
Sdivs (cm/s)	8.2 ± 1.6	8.3 ± 1.4	>0.05
Edivs (cm/s)	13.7 ± 2.1	13.3 ± 1.8	>0.05
Adivs (cm/s)	7.5 ± 1.8	7.7 ± 1.5	>0.05
Sdt (cm/s)	13.2 ± 1.7	12.7 ± 1.5	>0.05
Edt (cm/s)	16 ± 2.6	15 ± 2.5	>0.05

(Continued)

Table 9. (Continued)

	M694V mutation (+) n = 38 (mean ± SD)	M694V mutation (-) n = 33 (mean ± SD)	p-value
Adt (cm/s)	13.1 ± 3.3	12.6 ± 8.3	>0.05
The aortic elasticity parameters			
Aortic strain, (%)	0.33 ± 0.1	0.37 ± 0.12	>0.05
Ep (NxM ²)	119.8 ± 45.5	111.5 ± 44.1	>0.05
Ep*	2.1 ± 0.8	1.8 ± 0.7	>0.05
Distensibility (10 ⁻⁶ cm ² dyne ⁻¹)	1.9 ± 0.9	2.1 ± 0.8	>0.05
β SI	1.2 ± 0.5	1 ± 0.3	>0.05
The time-domain HRV parameters			
SDNN (msn)	140,9 ± 34,4	143 ± 33,2	>0.05
SDANN (msn)	120,9 ± 31,3	124,1 ± 29,5	>0.05
SDNN index (msn)	85,7 ± 23,4	85,6 ± 20,2	>0.05
RMSSD (msn)	64,8 ± 29,9	61,3 ± 28,5	>0.05
pNN50 (%)	25 ± 12,5	24 ± 12,8	>0.05

CRP = C reactive protein; ESR = erythrocyte sedimentation rate; cQT = Corrected QT; QTd = QT interval dispersion; cQTd = corrected QT dispersion; LVPWTd = Left ventricular posterior wall end diastolic thickness; IVSTd = interventricular septum thickness diastolic; LVD = left ventricular end-diastolic dimension; LVs = left ventricular end-systolic dimension; LA = left atrium; AA = aortic annulus; LVM = left ventricle mass; LVMI = left ventricle mass index; RWT = relative wall thickness; EF ejection fraction; FS fractional shortening; Adivs = peak atrial contraction velocity for the interventricular septum; Adm = peak atrial contraction velocity for the left ventricle; Adt = peak atrial contraction velocity for the right ventricle; Edivs:peak early relaxation velocity for the interventricular septum; Edm:peak early relaxation velocity for the left ventricle; Edt:peak early relaxation velocity for the right ventricle; Eivs = peak early mitral inflow velocity; Sdivs:peak systolic velocity for the interventricular septum; Sdm:peak systolic velocity for the left ventricle; Sdt:peak systolic velocity for the right ventricle; Ep = pressure strain elastic modulus; Ep* = pressure strain normalized by diastolic pressure; β SI = aortic stiffness β index.

parameters to be similar to those found by Fidanci et al.⁵⁴ These results suggested diminished vagal and total activity.

Clinical findings are usually sufficient for the diagnosis of familial Mediterranean fever, and genetic testing is mostly performed to support the diagnosis. Although many mutations have been found so far, M694V, M680I, V726A, M694I, and E148Q mutations are responsible for 85% of cases.²⁷ In our country, M694V mutation is the most common in patients with familial Mediterranean fever.^{27,55,56} Although the molecular effects of the M694V mutations have not yet been understood, studies of familial Mediterranean fever patients have reported that the M694V mutation is the most deleterious in a homozygous genotype, and they also appear to be effective in heterozygous mutations.^{8,55,57} The M694V mutation is associated with a complicated clinical course and increased sensitivity to inflammatory diseases and cardiac involvement.⁵⁷ One study showed that the heart rate recovery 1 and heart rate recovery 2 values were a negative correlation with M694V homozygous mutation in familial Mediterranean fever children.⁵⁸ Contrary to previous studies, we additionally also evaluated the role of M694V mutations on cardiac function in children with familial Mediterranean fever. In our study, the most common mutation was M694V. We compared the clinical effects of the M694V mutation and data of the patients with and without the M694V mutation. We found that C-reactive protein and erythrocyte sedimentation rate levels were increased in children with the M694V mutation. We think that inflammation is more prevalent in children with the M694V mutations because they have a higher acute phase response. In familial Mediterranean fever children with the M694V mutation, mean QT and QTcd were longer; mitral E was higher; tricuspid Sd, Ed, Ad were increased; Ep, Ep*, aortic stiffness β index were higher; aortic strain and distensibility were lower; SDNN and SDANN were decreased, but not significantly different. Due to the small number of cases in each

group and the younger age at diagnosis of familial Mediterranean fever, we think that there are no significant difference cardiac functions in patients with the M694V mutation. Further research is needed to understand the effects of M694V mutation.

Colchicine is the mainstay of the treatment in familial Mediterranean fever and a well-developed anti-inflammatory drug. It has been used for more than 50 years for the prevention of acute inflammatory attacks and deposition of amyloid in patients with familial Mediterranean fever.⁵⁹ When used in recommended doses, colchicine reduces serum C-reactive protein values in rheumatic and cardiovascular diseases. The cardioprotective effects of colchicine in familial Mediterranean fever have been extensively studied. Colchicine prevents cardiac ischaemia and pericarditis by inhibiting the mitotic activity of neutrophils, platelets, and endothelial cells.^{60,61} It has been showed that colchicine also prevented recurrences of pericarditis in familial Mediterranean fever patients.⁶² A few studies have shown that colchicine may reduce the risk of coronary artery disease in familial Mediterranean fever patients by suppressing augmented atherosclerosis and preventing amyloid deposition.^{63,64} Sari et al.⁶⁵ found regular colchicine treatment may prevent atherosclerosis and endothelial dysfunction in familial Mediterranean fever patients. Several small case-control studies showed that the familial Mediterranean fever group regularly treated with colchicine had p wave and QT dispersion values comparable to healthy people.^{33,34,42} Ocal et al.⁶⁶ reported that one-year colchicine treatment in familial Mediterranean fever patients may reduce various ventricular repolarisation indices. The effect of colchicine on autonomic dysfunction is not known.¹² Nussinovich et al.⁶⁷ demonstrated that familial Mediterranean fever patients receiving colchicine treatment may have a decreased incidence of cardiac arrhythmias than recently diagnosed familial Mediterranean fever patients. All familial Mediterranean fever children were treated

continuously with colchicine in this study. Therefore, we do not know the impact on outcomes in children who did not receive colchicine. Further research is necessary for the cardioprotective effect of colchicine in familial Mediterranean fever patients.

In conclusion, familial Mediterranean fever patients are at risk for cardiovascular disease because of subclinical inflammation during the attack-free period. These patients should be followed more closely. Arterial stiffness index and heart rate variability parameters of patients should also be evaluated since subclinical effects can be better understood. Therefore, cardiovascular risk can be predicted in the early stages of the disease, and necessary precautions can be taken. Arrhythmia, pericarditis, impairment of both right and left ventricle functions, and ischaemic heart disease are important in the familial Mediterranean fever. We believe electrocardiography, conventional and tissue Doppler echocardiography, and 24-hour ambulatory Holter monitoring may be useful for children to be followed regularly after diagnosis. Compliance with colchicine therapy and improved disease control may help reduce the likelihood of arrhythmias in these patients. To the best of our knowledge, this is the first study in the literature that globally assesses several indices of cardiac autonomic functions using electrocardiography, conventional, tissue Doppler echocardiography, and 24-hour ambulatory Holter monitoring in children with familial Mediterranean fever.

There is a need for prospective studies in larger series in children with familial Mediterranean fever, including patients with amyloidosis, and evaluating the relationship between mutations of the Mediterranean fever gene and cardiac functions.

Authors' contribution. SYA, DG, and SY wrote the main manuscript text and SYA prepared tables. All authors reviewed the manuscript. All authors have participated in the work and have reviewed and agree with the content of the article.

Financial support. The authors received no financial support for the research and/or authorship of this article.

None of the article contents are under consideration for publication in any other journal or have been published in any journal.

No portion of the text has been copied from other material in the literature.

I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications and to cover fully any costs involved.

Competing interests. None.

References

- Heller H, Sohar E, Sherf L. Familial Mediterranean fever. *Arch Int Med* 1958; 102: 50–71.
- Bernot A, Clepet C, Dasilva C, The French FMF Consortium, et al. A candidate gene for familial Mediterranean fever. *Natur Genet* 1997; 17: 25–31.
- Goldfinger S. The inherited autoinflammatory syndrome: a decade of discovery. *Trans Am Clin Climatol Assoc* 2009; 120: 413–418.
- The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely the cause familial Mediterranean fever. *Cell* 1997; 90: 797–807.
- Knockaert DC. Cardiac involvement in systemic inflammatory diseases. *Eur Heart J* 2007; 28: 1797–1804. DOI: [10.1093/eurheartj/ehm193](https://doi.org/10.1093/eurheartj/ehm193).
- Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. *Arthritis Rheum* 1997; 40: 1879–1885. DOI: [10.1002/art.1780401023](https://doi.org/10.1002/art.1780401023).
- Ben-Chetrit E, Levy M. Familial Mediterranean fever. *Lancet* 1998; 351: 659–664. DOI: [10.1016/S0140-6736\(97\)09408-7](https://doi.org/10.1016/S0140-6736(97)09408-7).
- Colak B, Gurlek B, Yegin ZA, et al. The relationship between the MEFV genotype, clinical features, and cytokine-inflammatory activities in patients with familial mediterranean fever. *Ren Fail* 2008; 30: 187–191. DOI: [10.1080/08860220701810364](https://doi.org/10.1080/08860220701810364).
- Gang Gang N, Drenth JP, Langevitz P, et al. Activation of the cytokine network in familial Mediterranean fever. *J Rheumatol* 1999; 26: 890–897.
- Baysal T, Peru H, Oran B, et al. Left ventricular diastolic function evaluated with tissue Doppler imaging in children with familial Mediterranean fever. *Clin Rheumatol* 2009; 28: 23–28. DOI: [10.1007/s10067-008-0976-z](https://doi.org/10.1007/s10067-008-0976-z).
- Caliskan M, Gullu H, Yilmaz S, et al. Impaired coronary microvascular function in familial Mediterranean fever. *Atherosclerosis* 2007; 195: e161–e167. DOI: [10.1016/j.atherosclerosis.2007.06.014](https://doi.org/10.1016/j.atherosclerosis.2007.06.014).
- Canpolat U, Dural M, Aytemir K, et al. Evaluation of various cardiac autonomic indices in patients with familial Mediterranean fever on colchicine treatment. *Auton Neurosci Basic Clin* 2012; 167: 70–74. DOI: [10.1016/j.autneu.2011.11.001](https://doi.org/10.1016/j.autneu.2011.11.001).
- Tavil Y, Öztürk MA, Üreten K, et al. Assessment of aortic wall stiffness in patients with familial Mediterranean fever. *Jt Bone Spine* 2008; 75: 280–285. DOI: [10.1016/j.jbspin.2007.05.021](https://doi.org/10.1016/j.jbspin.2007.05.021).
- Cole TJ, Flegal KM, Nicholls D, et al. Body mass index cut offs to define thinness in children and adolescents: international survey. *Br Med J* 2007; 335: 194–197. DOI: [10.1136/bmj.39238.399444.55](https://doi.org/10.1136/bmj.39238.399444.55).
- Bazett HC. An analysis of the time relations of electrocardiograms. *Heart* 1920; 7: 353–355.
- Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. *Circulation* 1978; 58: 1072–1083. DOI: [10.1161/01.CIR.58.6.1072](https://doi.org/10.1161/01.CIR.58.6.1072).
- Silverman NH. Quantitative methods to enhance morphological information using M-mode, Doppler, and cross-sectional ultrasound. In: Silverman NH (ed.) *Pediatric Echocardiography*. Williams & Wilkins, Baltimore, 1993, pp 35–108.
- de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. *J Am Coll Cardiol* 1992; 20: 1251–1260. DOI: [10.1016/0735-1097\(92\)90385-z](https://doi.org/10.1016/0735-1097(92)90385-z).
- Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. *Circulation* 1977; 55: 613–618. DOI: [10.1161/01.CIR.55.4.613](https://doi.org/10.1161/01.CIR.55.4.613).
- Lage SG, Kopel L. Arterial elastic properties: comparison of results and units. *J Am Coll Cardiol* 1992; 20: 1046–1047. DOI: [10.1016/0735-1097\(92\)90209-6](https://doi.org/10.1016/0735-1097(92)90209-6).
- Stefanadis C, Stratos C, Boudoulas H, et al. Distensibility of the ascending aorta: comparison of invasive and non-invasive techniques in healthy men and in men with coronary artery disease. *Eur Heart J* 1990; 11: 990–996. DOI: [10.1093/oxfordjournals.eurheartj.a059639](https://doi.org/10.1093/oxfordjournals.eurheartj.a059639).
- Lacombe F, Dart A, Dewar E, et al. Arterial elastic properties in man: a comparison of echo-Doppler indices of aortic stiffness. *Eur Heart J* 1992; 13: 1040–1045. DOI: [10.1093/oxfordjournals.eurheartj.a060311](https://doi.org/10.1093/oxfordjournals.eurheartj.a060311).
- Heart Rate Variability: Standards of Measurement, Physiological Interpretation and Clinical Use. Task force of the European society of cardiology and the North American society of pacing and electrophysiology. *Circulation* 1996; 93: 1043–1065.
- Onen F. Familial Mediterranean fever. *Rheumatol Int* 2006; 26: 489–496. DOI: [10.1007/s00296-005-0074-3](https://doi.org/10.1007/s00296-005-0074-3).
- Yalçinkaya F, Özen S, Özçakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. *Rheumatology* 2009; 48: 395–398. DOI: [10.1093/rheumatology/ken509](https://doi.org/10.1093/rheumatology/ken509).
- Ece A, Çakmak E, Uluca Ü, et al. The MEFV mutations and their clinical correlations in children with familial Mediterranean fever in southeast Turkey. *Rheumatol Int* 2014; 34: 207–212. DOI: [10.1007/s00296-013-2858-1](https://doi.org/10.1007/s00296-013-2858-1).
- Cobankara V, Kiraz S. Ailesel Akdeniz Ateşi. *Hacettepe Tıp Dergisi* 2000; 31: 310–319.
- Farag Y, Sayed S, Mostafa FA, Marzouk H, Mohamed RH, Sobhy R. Cardiac repolarization abnormalities in children with familial Mediterranean fever. *Pediatr Rheumatol* 2022; 20: 1–7. DOI: [10.1186/s12969-022-00696-5](https://doi.org/10.1186/s12969-022-00696-5).

29. Koca B, Kasapçopur Ö., Bakari S, et al. QT dispersion and cardiac involvement in children with familial Mediterranean fever. *Cardiol Young* 2012; 22: 404–409. DOI: [10.1017/S1047951111001867](https://doi.org/10.1017/S1047951111001867).
30. Akcay A, Acar G, Sayarlioglu M, et al. QT dispersion and transmural dispersion of repolarization in patients with familial Mediterranean fever. *Mod Rheumatol* 2009; 19: 550–555. DOI: [10.3109/s10165-009-0196-7](https://doi.org/10.3109/s10165-009-0196-7).
31. Şahin M, Kır M, Makay B, et al. Cardiac autonomic functions in children with familial Mediterranean fever. *Clin Rheumatol* 2016; 35: 1237–1244. DOI: [10.1007/s10067-014-2714-z](https://doi.org/10.1007/s10067-014-2714-z).
32. Topal F, Tanindi A, Kurtoglu HG, et al. QT dispersion is not increased in familial mediterranean fever. *J Int Med Res* 2011; 39: 2006–2011. DOI: [10.1177/147323001103900547](https://doi.org/10.1177/147323001103900547).
33. Nussinovitch N, Livneh A, Katz K, et al. QT dispersion in uncomplicated familial Mediterranean fever. *Clin Rheumatol* 2010; 29: 1353–1356. DOI: [10.1007/s10067-010-1434-2](https://doi.org/10.1007/s10067-010-1434-2).
34. Nussinovitch U, Kaminer K, Nussinovitch M, et al. QT interval variability in familial Mediterranean fever: a study in colchicine-responsive and colchicine-resistant patients. *Clin Rheumatol* 2012; 31: 795–799. DOI: [10.1007/s10067-011-1926-8](https://doi.org/10.1007/s10067-011-1926-8).
35. Topaloglu R, Ozaltin F, Yilmaz E, et al. E148Q is a disease-causing MEFV mutation: a phenotypic evaluation in patients with familial Mediterranean fever. *Ann Rheum Dis* 2005; 64: 750–752. DOI: [10.1136/ard.2004.026963](https://doi.org/10.1136/ard.2004.026963).
36. Yalçinkaya F, Çakar N, Misirlioğlu M, et al. Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation-independent amyloidosis. *Rheumatology* 2000; 39: 67–72. DOI: [10.1093/rheumatology/39.1.67](https://doi.org/10.1093/rheumatology/39.1.67).
37. Panossian A, Hambartsumyan M, Panosyan L, et al. Plasma nitric oxide level in familial Mediterranean fever and its modulations by immunoguard. *Nitric Oxide - Biol Chem* 2003; 9: 103–110. DOI: [10.1016/j.niox.2003.08.005](https://doi.org/10.1016/j.niox.2003.08.005).
38. Tavil Y, Üreten K, Öztürk MA, et al. The detailed assessment of left and right ventricular functions by tissue Doppler imaging in patients with familial Mediterranean fever. *Clin Rheumatol* 2008; 27: 189–194. DOI: [10.1007/s10067-007-0676-0](https://doi.org/10.1007/s10067-007-0676-0).
39. Ardic I, Kaya MG, Yarlioglu M, et al. Assessment of heart rate recovery index in patients with familial Mediterranean fever. *Rheumatol Int* 2011; 31: 121–125. DOI: [10.1007/s00296-010-1550-y](https://doi.org/10.1007/s00296-010-1550-y).
40. Ozdemir O, Agras PJ, Aydin Y, et al. Assessment of cardiac functions using tissue Doppler imaging in children with familial Mediterranean fever. *Cardiol Young* 2012; 22: 188–193. DOI: [10.1017/S1047951111001168](https://doi.org/10.1017/S1047951111001168).
41. Kalkan GY, Bayram NA, Erten S, et al. Evaluation of left ventricle function by strain imaging in patients with familial Mediterranean fever. *Echocardiography* 2010; 27: 1056–1060. DOI: [10.1111/j.1540-8175.2010.01217.x](https://doi.org/10.1111/j.1540-8175.2010.01217.x).
42. Sari I, Arican Ö., Can G, et al. Assessment of aortic stiffness and ventricular functions in familial Mediterranean fever. *Anadolu Kardiyol Derg* 2008; 8: 271–278.
43. Terekeci HM, Ulusoy ER, Kucukarslan NM, et al. Familial Mediterranean fever attacks do not alter functional and morphologic tissue Doppler echocardiographic parameters. *Rheumatol Int* 2008; 28: 1239–1243. DOI: [10.1007/s00296-008-0648-y](https://doi.org/10.1007/s00296-008-0648-y).
44. Ceylan Ö., Özgür S, Örün UA, et al. Assessment of left ventricular functions with tissue Doppler, strain, and strain rate echocardiography in patients with familial Mediterranean fever. *Anadolu Kardiyol Derg* 2015; 15: 663–668. DOI: [10.5152/akd.2014.5544](https://doi.org/10.5152/akd.2014.5544).
45. Mitchell GF, Izzo JL Jr. Evaluation of arterial stiffness. In *Hypertension Primer*, 3rd ed. American Heart Association, Dallas, Tex, 2003: 351–355.
46. Pannier B, Guérin AP, Marchais SJ, et al. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. *Hypertension* 2005; 45: 592–596. DOI: [10.1161/01.HYP.0000159190.71253.c3](https://doi.org/10.1161/01.HYP.0000159190.71253.c3).
47. Pereira T, Maldonado J, Pereira L, et al. Aortic stiffness is an independent predictor of stroke in hypertensive patients. *Arq Bras Cardiol* 2013; 100: 437–443. DOI: [10.5935/abc.20130079](https://doi.org/10.5935/abc.20130079).
48. Yıldız M, Masathoglu S, Seymen P, et al. The carotid-femoral (aortic) pulse wave velocity as a marker of arterial stiffness in familial Mediterranean fever. *Can J Cardiol* 2006; 22: 1127–1131. DOI: [10.1016/S0828-282X\(06\)70949-7](https://doi.org/10.1016/S0828-282X(06)70949-7).
49. Sgouropoulou V, Stabouli S, Trachana M. Arterial stiffness in familial Mediterranean fever: correlations with disease-related parameters and colchicine treatment. *Clin Rheumatol* 2019; 38: 2577–2584. DOI: [10.1007/s10067-019-04601-6](https://doi.org/10.1007/s10067-019-04601-6).
50. Türkuçar S, Yıldız K, Küme T, et al. Does familial Mediterranean fever provoke atherosclerosis in children? Evaluation of arterial stiffness and serum endocan levels. *Clin Rheumatol* 2021; 40: 4199–4206. DOI: [10.1007/s10067-021-05721-8](https://doi.org/10.1007/s10067-021-05721-8).
51. Kaya H, Suner A, Koroglu S, et al. Heart rate variability in familial Mediterranean fever patients. *Eur J Rheumatol* 2014; 49: 58–61. DOI: [10.5152/eurjrheumatol.2014.013](https://doi.org/10.5152/eurjrheumatol.2014.013).
52. Moog P, Valda K, Eren OE, et al. A complex pattern of autonomic dysfunction in familial Mediterranean fever. Results from a controlled cross-sectional study. *Clin Exp Rheumatol* 2019; 121: 35–42.
53. Nussinovitch N, Esev K, Lidar M, et al. Normal heart rate variability in colchicine-resistant familial Mediterranean fever patients. *Isr Med Assoc J* 2015; 17: 306–309.
54. Fidancı K, Gulgun M, Demirkaya E, et al. Assessment of autonomic functions in children with familial Mediterranean fever by using heart rate variability measurements. *Int J Rheum Dis* 2017; 20: 2086–2092. DOI: [10.1111/1756-185X.12401](https://doi.org/10.1111/1756-185X.12401).
55. Toutou I. The spectrum of familial Mediterranean fever (FMF) mutations. *Eur J Hum Genet* 2001; 9: 473–483. DOI: [10.1038/sj.ejhg.5200658](https://doi.org/10.1038/sj.ejhg.5200658).
56. Urfalı M, Yilmaz G, Özkul B, Urfalı FE. Indirect evaluation of amyloid deposition by ultrasonography and its relationship with MEFV gene mutation in FMF patients. *J Clin Ultrasound* 2022; 51: 1–8. DOI: [10.1002/jcu.23409](https://doi.org/10.1002/jcu.23409).
57. Grimaldi MP, Candore G, Vasto S, et al. Role of the pycrin M694V (A2080G) allele in acute myocardial infarction and longevity: a study in the Sicilian population. *J Leukoc Biol* 2006; 79: 611–615. DOI: [10.1189/jlb.0705416](https://doi.org/10.1189/jlb.0705416).
58. Evrengül H, Yüksel S, Doğan M, et al. Deteriorated systolic blood pressure recovery and heart rate recovery after graded exercise in children with familial mediterranean fever. *Arch Rheumatol* 2017; 32: 244–249. DOI: [10.5606/ArchRheumatol.2017.6071](https://doi.org/10.5606/ArchRheumatol.2017.6071).
59. Imazio M, Nidorf M. Colchicine and the heart. *Eur Heart J* 2021; 42: 2745–2760. DOI: [10.1093/eurheartj/ehab221](https://doi.org/10.1093/eurheartj/ehab221).
60. Gasparyan AY, Ayyvazyan L, Yessirkepov M, et al. Colchicine as an anti-inflammatory and cardioprotective agent. *Expert Opin Drug Metab Toxicol* 2015; 11: 1781–1794.
61. Yuksel S, Ayyvazyan L, Gasparyan AY. Familial Mediterranean fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. *Open Cardiovasc Med J* 2010; 4: 51–56.
62. Adler Y, Finkelstein Y, Guindo J, et al. Colchicine treatment for recurrent pericarditis. A decade of experience. *Circulation* 1998; 97: 2183–2185.
63. Ambartsymian SV. Myocardial infarction in patients with familial Mediterranean fever and cardiac lesions. *Georgian Med News* 2012; 204: 62–66.
64. Langevitz P, Livneh A, Neumann L, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. *Isr Med Assoc J* 2001; 3: 9–12.
65. Sari I, Karaoglu O, Can G, et al. Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. *Clin Rheumatol* 2007; 26: 1467–1473.
66. Ocal AG, Ocal L, Kup A, Eren H, Tezcan ME. Colchicine's effects on electrocardiographic parameters in newly diagnosed familial Mediterranean fever patients. *Zeitschrift für Rheumatologie* 2020; 79: 210–215. DOI: [10.1007/s00393-019-0642-7](https://doi.org/10.1007/s00393-019-0642-7).
67. Nussinovitch U, Stahi T, Livneh A. Evaluation of a proarrhythmic repolarization marker (Total cosine R to T) in patients with uncomplicated familial Mediterranean fever. *J Clin Rheumatol* 2020; 26: 334–337. DOI: [10.1097/RHU.0000000000001465](https://doi.org/10.1097/RHU.0000000000001465).